Bosentan treatment for Raynauds phenomenon and skin fibrosis in patients with Systemic Sclerosis and pulmonary arterial hypertension: an open-label, observational, retrospective study.
Raynaud?s phenomenon (RP) and cutaneous fibrosis are the distinctive manifestations of scleroderma, in which Endothelin-1 plays a fundamental pathogenetic role. Bosentan, an Endothelin-1 receptor antagonist used for the treatment of pulmonary arterial hypertension, retards the beginning of new sclerodermic digital ulcers (DU). This open-label, observational, retrospective study verified the effect of Bosentan on RP and skin fibrosis in sclerodermic outpatients affected by pulmonary arterial hypertension without DU. Fourteen subjects (13 women, 1 man; mean age 60 ± 7.5 years; ten with limited and four with diffuse scleroderma) were observed at baseline (T0) and after four (T1), twelve (T2), twenty-four (T3) and forty-eight (T4) weeks during treatment with Bosentan. They were evaluated for daily quantity and duration of RP attacks and skin thickness (using modified Rodnan total skin score, MRSS). Videocapillaroscopic evaluation was performed at T0 and T4. Bosentan decreased significantly the number and duration of RP attacks, beginning at T2 (p<0.05). Videocapillaroscopy showed significant improvement of microcirculatory patterns at T4 (p<0.05). MRSS decreased throughout the study, reaching the statistical significance at T3 and T4 (p<0.01) in the whole cohort. The present data suggest that Bosentan is effective in stabilizing the microcirculation involvement and in improving skin fibrosis irrespective of scleroderma patterns.
Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Italy. giordanon@unisi.it
N
N
Giordano
L
L
Puccetti
P
P
Papakostas
N
N
Di Pietra
F
F
Bruni
A L
AL
Pasqui
M
M
Acampa
V
V
Bocchi
V
V
Donati
M
M
Voglino
A
A
Fioravanti
A
A
Montella
A
A
Auteri
R
R
Nuti
M
M
Pastorelli
D000368:Aged; D000077300:Bosentan; D065128:Endothelin Receptor Antagonists; D065627:Familial Primary Pulmonary Hypertension; D005260:Female; D005355:Fibrosis; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011928:Raynaud Disease / Q000188:drug therapy*; D012189:Retrospective Studies; D012595:Scleroderma, Systemic / Q000188:drug therapy*; D012867:Skin / Q000473:pathology*; D013449:Sulfonamides / Q000627:therapeutic use*
D065128:Endothelin Receptor Antagonists; D013449:Sulfonamides; D000077300:Bosentan